Matt Cohen was appointed Director of Arrowhead Pharmaceuticals, Inc., effective June 12, 2026. As of November 6, 2026, Arrowhead Pharmaceuticals, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 16, 2026, naming 1 appointment (Form 8-K, June 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Arrowhead Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Arrowhead Pharmaceuticals, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-16. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Arrowhead Pharmaceuticals, Inc. files it.
Also on the record for Arrowhead Pharmaceuticals, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 5, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 6.6% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 9.64% of the class | 5%+ stakes | Source |
| July 31, 2026 | Stake report, Schedule 13G/A, by Vanguard Portfolio Management | 4.53% of the class | 5%+ stakes | Source |
| July 27, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 10.1% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G, by FMR LLC | 5.2% of the class | 5%+ stakes | Source |
| April 29, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.05% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.19% of the class | 5%+ stakes | Source |
| April 24, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 12.2% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| January 21, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 15% of the class | 5%+ stakes | Source |
| August 15, 2025 | Stake report, Schedule 13D/A, by Sarepta Therapeutics, Inc. | — | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Avoro Capital Advisors LLC | 8.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Arrowhead Pharmaceuticals, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Arrowhead Pharmaceuticals, Inc. and the records around it.
Arrowhead Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Who owns it
Companies that share a holder
- Avoro Capital Advisors LLC also filed stake reports on 18 other companies: Avalo Therapeutics, Inc. (Aug 2026), Hemab Therapeutics Holdings, Inc. (Aug 2026), Scribe Therapeutics, Inc. (Jul 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ACADIA PHARMACEUTICALS INC (Aug 2026)
- FMR LLC also filed stake reports on 761 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Arrowhead Pharmaceuticals, Inc.
Get an email when Arrowhead Pharmaceuticals, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Arrowhead Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Arrowhead Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Arrowhead Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 14 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-16 | In | Director | 2026-06-12 | 8-K, 2026-06-16 |
Who leads Arrowhead Pharmaceuticals, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Matt Cohen, appointed, effective 2026-06-12 (filed 2026-06-16).
New leaders reset buying decisions — get the Full Report on Arrowhead Pharmaceuticals, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Arrowhead Pharmaceuticals, Inc., with the record behind each one.
Find candidates like Director at Arrowhead Pharmaceuticals, Inc.Every change, in the filing's words
Appointed: Matt Cohen, Director, effective 2026-06-12
(d) Appointment of Dr. Matt Cohen as a Director On June 12, 2026, the Board of Directors of Arrowhead Pharmaceuticals, Inc. (the "Company") appointed Dr. Matt Cohen, M.D., M.B.A., as a director of the Company, effective June 12, 2026.
- Dr. Cohen has more than 25 years of experience in healthcare investing and portfolio management, and currently serves as Managing Director at Vida Ventures ("Vida").
- Prior to joining Vida in 2025, Dr. Cohen was a portfolio manager and the lead growth-focused healthcare investor at JP Morgan Asset Management ("JPMAM") since 2005.
- For almost a decade, he oversaw the portfolio management of growth healthcare assets for industry-leading multi-billion-dollar funds, including his roles as lead portfolio manager of the flagship JP Morgan Global Healthcare Fund and as co-portfolio manager of the JP Morgan Small Cap Growth Fund.
- For two decades, Dr. Cohen also served as the lead healthcare investor for the JP Morgan Small Cap Growth Fund, the JP Morgan Mid Cap Growth Fund, and the JP Morgan Growth Advantage Fund.
- In his capacity as portfolio manager and lead sector investor, he led teams of portfolio managers and research analysts focused on performing extensive due diligence and analysis on companies across the healthcare spectrum and market cap range, as part of the team's fundamental investment process.
- Before joining JPMAM, Dr. Cohen was a senior analyst at Medici Healthcare (2003-2005) and a senior analyst at Narragansett Asset Management (2000-2003), both New York-based healthcare hedge funds.
Tools for this story
Each opens in a new tab, filled in for Arrowhead Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.